NETCast

In this episode of the NET Podcast, Dr. Arshad meets with Dr. Soares, Dr. Shaheen, and Dr. Sonbol at the Tucson Regional Conference to discuss the evolving landscape of neuroendocrine tumors, focusing on recent studies such as the COMPETE study and the implications for treatment sequencing and patient care. They explore the importance of individualized treatment plans, the role of new therapies like cabozantinib, and the real-world challenges faced by patients, including financial toxicity. The conversation highlights the need for ongoing research and collaboration in the field.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

¡Bienvenidos a nuestro primer podcast en español! En este episodio, el Dr. Ismael Domínguez Rosado hablará con la Dra. Cecilia Carreras y la Dra. Mónica Isabel Meneses Medina para revisar la agenda de nuestra Conferencia Regional en la Ciudad de México. Luego, discutirán terapias locales y regionales para tumores endocrinos en México.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCAST, neuroendocrine experts Dr. Mosalem and Dr. Wahl meet with Taymeyah Al-Toubah discuss the latest advancements in neuroendocrine tumor treatments, focusing on peptide receptor radionuclide therapy (PRRT) with alpha and beta emitters. They delve into the safety and efficacy of new investigational agents, the challenges of hematological toxicity, and the importance of multidisciplinary teams in managing patient care. The conversation highlights the evolving landscape of neuroendocrine tumor therapies and the need for ongoing research and collaboration.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this podcast episode, neuroendocrine experts Dr. Liu and Dr. Gujarathi meet with Dr. Phan to discuss the latest advancements in neuroendocrine tumor research, focusing on innovative models for studying G1 and G2 neuroendocrine tumors, the implications of genetic mutations in pancreatic neuroendocrine tumors, and the future of drug screening and treatment protocols. The conversation highlights the importance of developing effective therapies tailored to individual patient profiles and the potential for new biomarkers to guide treatment decisions.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCAST, leading neuroendocrine experts Dr. Mohammed and Dr. Chauhan meet with Dr. Gangi to discuss their recent studies on innovative therapies for neuroendocrine tumors. Dr. Chauhan presents findings on Peltocetine, a new oral somatostatin receptor agonist, highlighting its efficacy in treating carcinoid syndrome. Dr. Mohammed shares insights on NP101, a combination therapy for metastatic neuroendocrine carcinomas, emphasizing its potential in enhancing treatment outcomes. The conversation explores the future of neuroendocrine cancer treatment, focusing on patient preferences and the importance of ongoing research.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, Dr. Jason Starr engages with patient advocacy leaders in the NET community to review highlights and insights from the 2024 NANETS Annual Symposium. Lisa Yen, Jessica Thomas, and Josh Mailman discuss the evolving role of patients in their care, the need for more therapies for neuroendocrine carcinoma, and the significance of building trust between patients and healthcare providers. The panelists share their experiences and strategies for empowering patients and bridging gaps in clinical trials and education.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr. Aman Chauhan joins Dr. Renuka Iyer to discuss the critical updates in neuroendocrine tumors, focusing on the AJCC staging system and its implications for clinical practice. The conversation covers the evolution of staging systems, the role of biomarkers like chromogranin A, the importance of endoscopists in management, and the outcomes for appendiceal neuroendocrine tumors. The episode emphasizes the need for updated guidelines to improve patient care and outcomes in the field of oncology.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

DLL3 approval in eSCLC and how it can be used in extrapulmonary PDNEC/small cell. Dr. Phan speaks with Dr. Jain about treatment options for neuroendocrine carcinoma.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

NET Regional Education Conference Jointly Provided by The University of Minnesota and The Mayo Clinic. Dr. Lou and Dr. Halfdanarson spoke with Dr. Phan and Dr. Chandrasekharan about Systemic Therapy for NETs Beyond SSAs (Including Sequencing) and Well-differentiated G3 NETs.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join us for Episode 24 of NETCast. Mayo Clinical Gastrointestinal Oncologist Dr. Jason Starr interviews Lisa Yen from LACNETS and Stephanie Alband from INCA and The PheoPara Alliance, patient advocacy groups that partner with NANETS. Join us as we discuss ways we are Bridging the Gap for patient advocacy.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.